Journal of Pain & Relief
Open Access

Discogenic low back pain; Intervertebral disc degeneration; Inflammation; Oxidative stress; Matrix degradation; Neuronal remodelling; Molecular mechanisms; Musculoskeletal disorders

Introduction

Low Back Pain (LBP) is one of the leading causes of disability worldwide, with Discogenic Low Back Pain (DLBP) accounting for a significant proportion of cases. DLBP originates from degeneration of the Intervertebral Disc (IVD), the fibrocartilage structure situated between vertebrae that act as a shock absorber. The condition is often characterized by persistent pain and discomfort, and it has become a major contributor to healthcare costs due to its chronic nature and complex pathophysiology. Recent advances in molecular biology and genetics have provided deeper insights into the cellular and biochemical changes underlying disc degeneration and pain. While mechanical stress and aging have been long recognized as key factors contributing to disc degeneration, the molecular mechanisms that drive DLBP remain an area of active research. This review aims to summarize the current understanding of these mechanisms, focusing on the role of inflammation, oxidative stress, extracellular matrix (ECM) degradation, and neuronal changes within the IVD [1,2].

Description

Intervertebral disc structure and function

The intervertebral disc is composed of three primary regions: the annulus fibrosus (AF), nucleus pulposus (NP), and the cartilaginous endplate. The NP acts as a gel-like core, providing compressive resistance, while the AF surrounds the NP in concentric lamellae, offering tensile strength. Healthy discs have a highly hydrated structure and a rich extracellular matrix (ECM) composed of proteoglycans, collagen fibers, and other molecules that allow for load-bearing and cushioning functions [3].

Molecular pathophysiology of disc degeneration

The degenerative process of the IVD is initiated by a variety of factors, including aging, mechanical stress, and genetic predisposition. Over time, the disc loses water content, leading to a reduction in its elasticity and a decline in its ability to resist mechanical forces. The molecular events that drive this degeneration are complex, involving changes in the ECM composition, cellular apoptosis, and inflammation.

Extracellular matrix degradation: The ECM is central to disc function, and its degradation is one of the earliest signs of disc degeneration. Key enzymes involved in ECM degradation include matrix metalloproteinases (MMPs) and aggrecanases, which break down collagen and proteoglycans, respectively. Excessive activity of these enzymes leads to the loss of disc integrity and contributes to disc instability [4,5].

Inflammation and cytokines: Inflammatory processes play a pivotal role in DLBP. Activated disc cells, particularly in the NP and AF, release pro-inflammatory cytokines such as interleukins (IL-1β, IL-6) and tumor necrosis factor-alpha (TNF-α). These cytokines promote matrix degradation and further contribute to pain by sensitizing nociceptive neurons. Additionally, immune cells infiltrate the degenerated disc, amplifying the inflammatory response and creating a vicious cycle that exacerbates degeneration.

Oxidative stress: Oxidative stress is another key factor in disc degeneration. The imbalance between the production of Reactive Oxygen Species (ROS) and the disc's antioxidant defenses leads to cellular damage and ECM degradation. Mitochondrial dysfunction in disc cells can also contribute to oxidative stress, accelerating the degeneration of the disc [6,7].

Neuronal remodelling: One of the most intriguing aspects of DLBP is the involvement of neuronal changes. As the disc degenerates, nerve fibers invade the IVD, particularly in areas of the AF and endplate. These nerve fibers release neuropeptides, such as substance P, which are involved in pain transmission. In addition, changes in the neurotrophic factor expression can result in hyperexcitability of the dorsal root ganglia (DRG), further contributing to pain sensation.

Genetic and epigenetic factors

Genetic susceptibility plays a significant role in disc degeneration and DLBP. Several studies have identified genetic polymorphisms in genes encoding ECM components, inflammatory mediators, and pain-related pathways that may predispose individuals to disc degeneration. Additionally, epigenetic changes, such as DNA methylation and histone modifications, can alter gene expression in response to environmental factors, further contributing to disc degeneration and pain [8].

Discussion

The molecular mechanisms involved in discogenic low back pain are multifactorial and complex. Disc degeneration, once thought to be mainly a result of mechanical wear and tear, is now recognized as a dynamic process involving cellular signaling pathways, ECM remodelling, inflammation, oxidative stress, and neuronal plasticity. These processes create a feedback loop that amplifies disc degeneration and pain over time, leading to chronic symptoms [9].

Understanding the molecular mechanisms of DLBP provides valuable insights into potential therapeutic strategies. Targeting inflammation through the use of anti-inflammatory agents, for example, could help alleviate pain and slow degeneration. Similarly, the development of therapies that inhibit ECM degradation or promote the repair of damaged tissue holds promise for the treatment of DLBP. In addition to pharmacological interventions, regenerative medicine approaches, such as stem cell therapy, gene therapy, and tissue engineering, are being explored as potential treatments for disc degeneration. These therapies aim to repair or replace damaged disc tissue, restore ECM homeostasis, and promote disc regeneration [10].

Conclusion

Discogenic low back pain remains a significant clinical challenge due to the complex molecular mechanisms that drive its development and progression. Recent research has provided a deeper understanding of the cellular, biochemical, and genetic factors that contribute to disc degeneration and pain. Although no single therapeutic approach is likely to be effective for all patients, advances in molecular biology and regenerative medicine offer promising avenues for the treatment and prevention of DLBP. Continued research into the molecular pathways involved in disc degeneration is essential to developing more targeted and effective treatments for this debilitating condition

1. Tamae PE, Dos Santos AV, Simão MLS, Canelada ACN, Zampieri KR, et al. (2020) Can the associated use of negative pressure and laser therapy be a new and efficient treatment for Parkinson’s pain? A comparative study. J Alzheimers Dis Parkinsonism 10: 1-6.

Google Scholar

2. Panhóca VH, Nogueira MS, Bagnato VS (2020) Treatment of facial nerve palsies wit laser and endermotherapy: a report of two cases. Laser Phys 18: 15601.

Indexed at, Google Scholar, Crossref

3. Canelada ACN, Carbinatto FM, de Aquino Junior AE, Bagnato VS (2021) A Case Report on the Use of a Conjugated System ofMyofascialRelease for Shoulder Capsulitis. J Nov Physiother 11: 476.

Google Scholar

4. Canelada ACN, Vitor Hugo Panhóca, Carbinatto FM, Bagnato VS, De Aquino Junior AE (2022) Can a new synergistic proposal involving photobiomodulation and myofascial release accelerate the evolution of adhesive capsulitis and tendinopathies? J Nov Physiother 12: 535.

Google Scholar

5. Canelada ACN, De Aquino Junior AE, Carbinatto FM, Panhóca VH, Simão G, et al. (2022) The Synergy of Photobiomodulation and Myofascial Release in Upper Limb Injuries-Case Series. J Nov Physiother 12: 515.

Google Scholar

6. Ajimsha MS, Al-Mudahka Nr, Al-Madzhar JA (2015) Effectiveness of myofascial release: Systematic review of randomized controlled trails. J Bodyw Mov Ther 19: 102-112.

Indexed at, Google Scholar, Crossref

7. Karu TL (2000) Mechanisms of low-power laser light action on cellular level. In: Karu, T.I. & Lubart, R. Effects of low-power light on biological systems V. Amsterdam, Netherlands: Proceedingsof SPIE 4159: 1-17.

Indexed at, Google Scholar, Crossref

8. Dong W, Goost H, Lin X, Burger C, Paul C, et al. (2015) Treatments for Shoulder Impingement Syndrome: Aprisma Systematic Reviewand Network Meta Analysis. Medicine 94:10.

Indexed at, Google Scholar, Crossref

9. Linaker CH, Walker-Bone K (2015) Shoulder disorders and occupation. Best Pract Res Clin Rheumatol 29: 405-423.

Indexed at, Google Scholar, Crossref

10. Rees JD, Wilson AM, Wolman RL (2006) Current concept sin the management of tendon disorders. Rheumatology 45: 508-521.

Indexed at, Google Scholar, Crossref